Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Immunotherapy Agents and ADCs May Redefine Early-Stage TNBC Management

May 18th 2025

Alexis LeVee, MD, discusses treatment challenges associated with TNBC and ongoing trials that may improve outcomes for patients with early-stage disease.

Dr Vlachou on the Rationale for Evaluating Perioperative Enfortumab Vedotin Plus Pembrolizumab in Upper Tract Urothelial CancerCancer

May 16th 2025

Evangelia Vlachou, MD, discusses the investigation of enfortumab vedotin plus pembrolizumab as perioperative therapy in upper tract urothelial cancer.

Dr Ali on the Efficacy of CDK4/6 Inhibition in ER+, HER2+ Breast Cancer

May 16th 2025

Azka Ali, MD, discusses how data from the PATINA trial inform the role of CDK4/6 inhibition in ER-positive, HER2-positive breast cancer.

Dr Tarantino on the Potential Relevance of the DESTINY-Breast09 Trial in HER2+ Breast Cancer

May 16th 2025

Paolo Tarantino, MD, PhD, discusses potentially practice-changing breast cancer research that will be presented at the 2025 ASCO Annual Meeting.

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer

May 16th 2025

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.

Dr Bhat on Using BTK Degraders and Bispecific Antibodies to Address Challenges With R/R CLL Management

May 16th 2025

Seema A. Bhat, MD, discusses the ongoing development of BTK degraders and novel bispecific antibodies in relapsed/refractory CLL.

Neoadjuvant Letrozole/Entrectinib Shows Limited Activity in Invasive Lobular Breast Cancer

May 16th 2025

Frontline endocrine therapy plus entrectinib failed to decrease RCB to 0/1 in patients with invasive lobular breast carcinoma.

OncLive Polls Spotlight Phase 3 Breast Cancer Studies Generating Buzz Ahead of ASCO 2025

May 16th 2025

Breast cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott

May 15th 2025

Pant and Elliott discuss research seeking to extend the benefits of cancer vaccines as cancer management and prevention strategies.

Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer

May 15th 2025

Neoadjuvant data from the ADAPTcycle trial confirmed the limited benefit of chemotherapy over endocrine therapy in high-risk HR-positive breast cancer.

Dr Sabari on the Activity of Zongertinib in Pretreated, Advanced, HER2-Mutated NSCLC

May 15th 2025

Joshua K. Sabari, MD, discusses how phase 1 efficacy data with zongertinib in HER2-mutant NSCLC lay the foundation for future research with the agent.

Dr LeVee on Ongoing Research With Immunotherapy and ADCs in TNBC

May 15th 2025

Alexis LeVee, MD, discusses ongoing trials investigating immunotherapy agents and antibody-drug conjugates that may challenge the current SOC for TNBC.

Dr Eskander on Interpreting Biomarker Analyses From the DUO-E Trial in pMMR Endometrial Cancer

May 15th 2025

Ramez N. Eskander, MD, discusses the limitations of biomarker analyses for guiding treatment decisions in pMMR endometrial cancer.

FDA Approves Retifanlimab for Advanced Anal Cancer

May 15th 2025

The FDA approved frontline retifanlimab/chemotherapy for metastatic SCAC and retifanlimab monotherapy for metastatic SCAC with progression on chemotherapy.

FDA Green Lights Companion Diagnostic for Telisotuzumab Vedotin in NSCLC

May 15th 2025

The FDA has approved the VENTANA MET (SP44) RxDx Assay as a companion diagnostic for telisotuzumab vedotin in non–small cell lung cancer.

Pembrolizumab-Based Regimen Yields PFS Benefit in Platinum-Resistant Ovarian Cancer

May 15th 2025

Pembrolizumab/paclitaxel with or without bevacizumab improved PFS vs placebo/chemotherapy with or without bevacizumab in platinum-resistant ovarian cancer.

Dr Perez on the FDA Approval of Belzutifan for Advanced Pheochromocytoma and Paraganglioma

May 14th 2025

Kimberly Perez MD, discusses the FDA approval of belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting

May 14th 2025

To prepare for the 2025 ASCO Annual Meeting, breast cancer experts share the abstracts and discussions they’re most excited to see at the meeting.

Genetic Insights and Novel Trial Designs Contribute to an Era of Individualized MDS Management

May 13th 2025

Rami Komrokji, MD, discusses the evolution of lower-risk MDS treatments that reflect novel classification systems and trials exploring novel therapies.

Frontline Belrestotug Plus Dostarlimab Misses PFS End Point in PD-L1–High NSCLC

May 13th 2025

Belrestotug plus dostarlimab did not improve PFS vs dostarlimab monotherapy in PD-L1–high NSCLC, supporting the termination of belrestotug development.